Mechanisms
Narrative review separates settled from unresolved: Lp(a) firmly drives MI and aortic stenosis, but its role in AF and in-stent restenosis stays unclear (Int J Mol Sci 2024)
Original title: Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review
This narrative review surveys Lp(a)'s well-established proatherogenic, pro-inflammatory, and prothrombotic contributions to cardiovascular disease, noting that while Lp(a) measurement is now widely available, effective lowering therapies remain limited, with antisense oligonucleotide trials showing promising early reductions. The review distinguishes areas of stronger evidence, where Lp(a) is a credible therapeutic target for myocardial infarction, calcific aortic stenosis, and cerebrovascular events, from more controversial or unresolved territory, including Lp(a)'s role in atrial fibrillation, in-stent restenosis, cardiac allograft vasculopathy, and bioprosthetic aortic valve degeneration. By cataloguing where the literature agrees and where it conflicts across these specific clinical scenarios, the review aims to sharpen future research priorities for clarifying Lp(a)'s precise role in each condition.
Original abstract
Lipoprotein (a) is a complex lipid molecule that has sparked immense interest in recent years, after studies demonstrated its significant association with several cardiovascular conditions. Lp(a) promotes cardiovascular disease through its combined proatherogenic, pro-inflammatory, and prothrombotic effects. While the measurement of Lp(a) has become widely available, effective methods to reduce its concentration are currently limited. However, emerging data from ongoing clinical trials involving antisense oligonucleotides have indicated promising outcomes in effectively reducing Lp(a) concentrations. This may serve as a potential therapeutic target in the management and prevention of myocardial infarction, calcific aortic stenosis, and cerebrovascular accidents. In contrast, the role of Lp(a) in atrial fibrillation, in-stent restenosis, cardiac allograft vasculopathy, and bioprosthetic aortic valve degeneration remains unclear. This review article aims to thoroughly review the existing literature and provide an updated overview of the evidence surrounding the association of Lp(a) and these cardiovascular diseases. We seek to highlight controversies in the existing literature and offer directions for future investigations to better understand Lp(a)'s precise role in these conditions, while providing a summary of its unique molecular characteristics.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.